TABLE 3.
Summary of study outcomesa
| Outcome | i.v. (n = 66) | Oral (n = 66) | Treatment difference (95% confidence interval) |
|---|---|---|---|
| 30-day treatment failure | 4 (6.1%) | 13 (19.7%) | 13.6% (2.4%, 24.8%)b |
| 30-day mortality | 0 (0.0%) | 3 (4.5%) | 4.5% (−0.5%, 9.6%) |
| 30-day relapse | 2 (3.0%) | 5 (7.6%) | 4.5% (−3.1%, 12.2%) |
| 30-day readmission | 3 (4.5%) | 6 (9.1%) | 4.5% (−4.0%, 13.1%) |
| 90-day treatment failure | 10 (15.2%) | 17 (25.8%) | 10.6% (−3.0%, 24.2%) |
| 90-day mortality | 1 (1.5%) | 4 (6.1%) | 4.5% (−1.9%, 11.0%) |
| 90-day relapse | 4 (6.1%) | 6 (9.1%) | 3.0% (−6.0%, 12.0%) |
| 90-day readmission | 7 (10.6%) | 9 (13.6%) | 3.0% (−8.1%, 14.2%) |
| Acute kidney injury during treatment | 2 (3.0%) | 0 (0.0%) | −3.0% (−7.2%, 1.1%) |
a
Treatment difference is the outcome frequency in the oral group minus the outcome frequency in the i.v. group (in percentage points), with a corresponding 95% confidence interval.
b
Test for noninferiority of oral therapy based on a preestablished margin of 10 percentage points: P = 0.741.